

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED**  
**北京同仁堂國藥有限公司**  
*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 3613)**

**CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR  
AND COMPOSITION OF THE BOARD COMMITTEES  
AND  
RE-DESIGNATION OF DIRECTOR**

The Board announces that with effect from 13 March 2023:

- (i) Mr. Zhao Zhong Zhen has tendered his resignation to the Board as an Independent Non-executive Director and ceased to be the chairman of the remuneration committee of the Company, a member of each of the audit committee, nomination committee and competition supervisory committee of the Company;
- (ii) Mr. Xu Hong Xi has been appointed as an Independent Non-executive Director, the chairman of the remuneration committee of the Company, a member of each of the audit committee, nomination committee and competition supervisory committee of the Company; and
- (iii) Ms. Feng Li, an Executive Director, has been re-designated as a Non-executive Director.

**CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPOSITION OF  
THE BOARD COMMITTEES**

The board of directors (the “**Board**”) of Beijing Tong Ren Tang Chinese Medicine Company Limited (the “**Company**”) hereby announces the following change of independent non-executive director of the Company (“**Independent Non-executive Director**”) and composition of the board committees of the Company with effect from 13 March 2023:

### **Mr. Zhao Zhong Zhen**

Mr. Zhao Zhong Zhen (“**Mr. Zhao**”) has tendered his resignation to the Board as an Independent Non-executive Director due to other business commitment and personal endeavours. As a result, Mr. Zhao ceased to be the chairman of the remuneration committee of the Company, a member of each of the audit committee, nomination committee and competition supervisory committee of the Company.

Mr. Zhao has confirmed that he has no disagreement with the Board or the Company and there is no matter in relation to his resignation that needs to be brought to the attention of shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhao for his invaluable contribution made to the Company during his tenure of service.

### **Mr. Xu Hong Xi**

Mr. Xu Hong Xi (“**Mr. Xu**”) has been appointed as an Independent Non-executive Director, the chairman of the remuneration committee of the Company, a member of each of the audit committee, nomination committee and competition supervisory committee of the Company.

The biographical details of Mr. Xu are set out as follows:

**Xu Hong Xi**, aged 61, is currently the chief professor of Shanghai University of Traditional Chinese Medicine, the honorary dean of the School of Pharmacy and the head of Shanghai College Engineering Research Center for Innovative Pharmaceutical Research and Development of Chinese Medicine. Mr. Xu serves as a distinguished professor of Organization Department of the Central Committee of the Chinese Communist Party, the first batch “Shanghai Distinguished Expert” and concurrently serves as the secretary-general of Chinese Medicine Academic Disciplinary Assessment team of the State Council Academic Degrees Committee, a member of Chinese Medicine Professional Education Steering Committee under Ministry of Education, a member of Chinese Pharmacopoeia Commission, the chairman of Chinese Medicine Experimental Pharmacology Branch of China Association of Chinese Medicine, the chairman of Chinese Medicine Professional Committee of Shanghai Pharmaceutical Association, the co-chairman of International Conference of the Modernization of Chinese Medicine. Mr. Xu successively served as the scientific officer of Chinese Medicine Research Centre at the Chinese University of Hong Kong, the deputy general manager and senior medical advisor of Hutchison Whampoa (China) Limited, a director and the R & D director of Shanghai Hutchison Pharmaceuticals Limited, and the deputy director of Hong Kong Jockey Club Institute of Chinese Medicine. Mr. Xu graduated from Shanghai University of Traditional Chinese Medicine in 1983 and 1989 with a bachelor’s degree and master’s degree, respectively, and obtained his Ph.D. degree in Pharmaceutical Sciences in 1994 from Toyama Medical and Pharmaceutical University in Japan, and conducted postdoctoral research in National University of Singapore and Dalhousie University in Canada between 1994 and 1998.

Mr. Xu shall hold office until the next following general meeting of the Company and if re-elected by the Shareholders thereat, will be subject to retirement by rotation and re-election at annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. An appointment letter (the “**Letter**”) was entered into between the Company and Mr. Xu on 13 March 2023 for a period of three years. Pursuant to the Letter, Mr. Xu is entitled to a fixed director’s fee of HK\$24,000 per month, which is determined by the Board upon the recommendation of the remuneration committee of the Company by reference to his experience and responsibilities in the Company and the prevailing market conditions and is subject to an annual review.

As at the date of this announcement, Mr. Xu does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

As at the date of this announcement, Mr. Xu has not held any directorship in any Hong Kong or overseas listed companies in the last three years. Save as disclosed above, Mr. Xu does not have any relationship with any director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company nor does he hold any other position with the Company or any of its subsidiaries.

Mr. Xu has confirmed his independence pursuant to Rule 3.13 of the Listing Rules.

Save as disclosed above, Mr. Xu has confirmed that there is no other information relating to him that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the Shareholders in connection with the aforesaid appointment.

The Board would like to extend its warmest welcome to Mr. Xu for joining the Board.

## **RE-DESIGNATION OF DIRECTOR**

The Board further announces that Ms. Feng Li (“**Ms. Feng**”), currently an executive director of the Company (“**Executive Director**”), has been re-designated as a non-executive director of the Company (“**Non-executive Director**”) with effect from 13 March 2023 due to other business commitment.

The biographical details of Ms. Feng are set out as follows:

**Feng Li**, aged 47, was appointed as an Executive Director on 12 August 2022. Ms. Feng currently serves as a non-executive director of Tong Ren Tang Technologies Co. Ltd. (a company listed on the Stock Exchange, stock code: 1666), a controlling Shareholder (“**Controlling Shareholder**”, as defined in the Listing Rules) of the Company, and the deputy general manager and the secretary to the board of directors of Beijing Tong Ren Tang Company Limited (a company listed on the Shanghai Stock Exchange, stock code: 600085), a Controlling Shareholder. Ms. Feng joined Beijing Tong Ren Tang Group in March 2012 and was formerly served as the manager of the Internal Audit and Legal Department, the assistant to the general manager and the manager of the Economic Operation Department of the Company. Prior to joining Beijing Tong Ren Tang Group, Ms. Feng worked as a senior audit manager at PricewaterhouseCoopers Zhongtian LLP. Ms. Feng graduated from the Department of International Economics of Peking University in 1998 with a bachelor’s degree in economics and she is also a certified public accountant in China (non-practicing).

Ms. Feng shall hold office until the next following general meeting of the Company and if re-elected by the Shareholders thereat, will be subject to retirement by rotation and re-election at annual general meeting of the Company at least once every three years in accordance with the articles of association of the Company. A service contract (the “**Contract**”) was entered into between the Company and Ms. Feng on 13 March 2023 for a period of three years. Pursuant to the Contract, Ms. Feng will not receive any director’s fee as a Non-executive Director. For the year ended 31 December 2022, Ms. Feng did not receive any director’s fee as an Executive Director.

As at the date of this announcement, Ms. Feng does not have any interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Ms. Feng (i) has not held any directorship in any Hong Kong or overseas listed companies in the last three years; (ii) does not have any relationship with any director, senior management or substantial or Controlling Shareholder(s) (as defined in the Listing Rules); and (iii) does not hold any other position with the Company or any of its subsidiaries.

Save as disclosed above, Ms. Feng has confirmed that there is no other information relating to her that is required to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters which need to be brought to the attention of the Shareholders in connection with the aforesaid appointment.

By order of the Board  
**Beijing Tong Ren Tang**  
**Chinese Medicine Company Limited**  
**Ding Yong Ling**  
*Chairman*

Hong Kong, 13 March 2023

As at the date of this announcement, the composition of the Board is as follows:

***Executive Directors:***

Ms. Ding Yong Ling (*Chairman*)  
Mr. Chen Fei  
Ms. Lin Man

***Independent Non-executive Directors:***

Mr. Tsang Yok Sing, Jasper  
Mr. Zhao Zhong Zhen (*resigned on 13 March 2023*)  
Mr. Xu Hong Xi (*appointed on 13 March 2023*)  
Mr. Chan Ngai Chi

***Non-executive Director:***

Ms. Feng Li (*re-designated on 13 March 2023*)